One year after receiving CRISPR gene editing therapy at CHOP, a Delaware County baby is thriving, and doctors want to expand ...
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. The FDA has issued draft guidance that could speed up approval pathways for rare ...
CRISPR gene therapy Casgevy can nearly eliminate sickle cell crises, but difficult stem‑cell collection is delaying access ...
February 25, 2026 marks one year since KJ, an infant born with severe carbamoyl phosphate synthetase 1 (CPS1) deficiency, became the world's first person to receive a personalized CRISPR-based gene ...
8d
Gene Editing Has Struggled To Go Commercial. This Nobel Laureate Has A $1 Billion Plan To Fix That.
Crispr’s ability to cut genetic code like scissors has just started to turn into medicines. Now, gene editing pioneer ...
A new light-based sensor detects cancer markers at near-zero concentrations.
A version of this Priestley Medal address will be presented at the American Chemical Society Spring 2026 meeting ...
The first gene therapies approved to treat sickle cell disease in December 2023 are struggling on the market. But there are ...
The company could finally be ready to deliver on years of promise.
Revvity's Dharmacon All-in-one lentiviral platform has expanded to include whole-genome library options for CRISPR knockout (CRISPRko), CRISPR interference (CRISPRi), and CRISPR activation (CRISPRa).
Forget Vertex Pharmaceuticals -- CRISPR Therapeutics is a better buy right now.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results